Treating heart failure through innovative RNA-therapies
HAYA Therapeutics SA
Incorporated
02.07.2019Headquarters
EpalingesSupport
HAYA Therapeutics is dedicated to treating heart failure through the discovery and development of innovative first-in-class RNA-based therapeutics, with a specific focus on long noncoding RNAs.
News
New Startup Innovation Projects set to advance their technologies (startupticker.ch)
2025 WEF Technology Pioneers highlight two Swiss Startups (startupticker.ch)
Un jubilé synonyme de renaissance (startupticker.ch)
HAYA Therapeutics banks $65 million Series A funding (startupticker.ch)
HAYA Therapeutics secures USD 65M to advance RNA-guided therapies for chronic and age-related diseases (venturelab.swiss)
Recognition for Swiss innovators across the globe (startupticker.ch)
Seasoned executives join Swiss startups (startupticker.ch)
Healthtech startups set for growth (startupticker.ch)
Set for growth: startups rely on experienced leaders (startupticker.ch)
The most promising Swiss biotech startups and scale-ups of 2024, according to investors (TOP 100)
HAYA Therapeutics secures USD 1 billion deal with Lilly to target obesity through RNA platform (venturelab.swiss)
HAYA Therapeutics wins Major Collaboration with Lilly (startupticker.ch)
Erfahrene Expertinnen und Experten verstärken Startup-Management (startupticker.ch)
Inaugural European entrepreneur award crowns HAYA Therapeutics Founders (startupticker.ch)
Swiss Economic Awards: 9 Startups im Finale (startupticker.ch)
ZKB Pionierpreis Technopark shortlists 11 startups (startupticker.ch)
A biotech company ranks first at the TOP 100 Swiss Startup Award (startupticker.ch)
HAYA Therapeutics wins the top prize at the TOP 100 Swiss Startup Award 2023 (TOP 100)
The 18 most promising biotech startups, according to investors (TOP 100)
Videos and Presentations
Startup Champions Seed Night 2018